Edgewise Therapeutics, Inc. (EWTX) Ownership
EWTX ownership summary
as of October 18, 2026- Institutions
- 112.3% of shares outstanding
- Insiders
- 0.49% of shares outstanding
- Shares outstanding
- 108.6M
- Float
- 74.3M shares available to trade
- Short interest
- 14.56% 11.2M shares short
- Days to cover
- 6.94 short interest up 17.6% vs prior month
- Institutions 112.31%
- Insiders 0.49%
EWTX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Orbimed Advisors LLC | 14.29% | 15.5M | $577.1M | — | June 30, 2026 |
| 2 | Paradigm Biocapital Advisors LP | 9.41% | 10.2M | $379.9M | +2.9M (+38.7%) | June 30, 2026 |
| 3 | RA Capital Management, LLC | 7.73% | 8.4M | $312.1M | −2.0M (−19.5%) | June 30, 2026 |
| 4 | BlackRock Inc | 6.08% | 6.6M | $245.7M | +133,345 (+2.1%) | June 30, 2026 |
| 5 | Jupiter Topco LLC | 5.59% | 6.1M | $225.9M | +6.1M (0.0%) | June 30, 2026 |
| 6 | HHG PLC | 5.45% | 5.9M | $220.0M | +1.3M (+29.5%) | March 31, 2026 |
| 7 | FMR Inc | 5.05% | 5.5M | $204.1M | +4.5M (+439.7%) | June 30, 2026 |
| 8 | Novo A/S | 4.93% | 5.3M | $199.0M | — | June 30, 2026 |
| 9 | Driehaus Capital Management LLC | 4.35% | 4.7M | $175.9M | +250,681 (+5.6%) | June 30, 2026 |
| 10 | Perceptive Advisors LLC | 4.03% | 4.4M | $162.7M | −50,000 (−1.1%) | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 3.55% | 3.9M | $143.6M | +72,509 (+1.9%) | June 30, 2026 |
| 12 | Baker Bros Advisors LP | 3.41% | 3.7M | $137.7M | −2.9M (−43.7%) | June 30, 2026 |
| 13 | Siren, L.L.C. | 2.93% | 3.2M | $118.4M | −1.2M (−28.1%) | June 30, 2026 |
| 14 | Cormorant Asset Management, LLC | 2.31% | 2.5M | $93.3M | −750,000 (−23.0%) | June 30, 2026 |
| 15 | Geode Capital Management, LLC | 2.00% | 2.2M | $80.9M | +384,232 (+21.5%) | June 30, 2026 |
| 16 | AllianceBernstein L.P. | 1.95% | 2.1M | $78.8M | +396,855 (+23.0%) | June 30, 2026 |
| 17 | Integral Health Asset Management, LLC | 1.84% | 2.0M | $74.4M | +400,000 (+25.0%) | June 30, 2026 |
| 18 | BRAIDWELL LP | 1.84% | 2.0M | $74.3M | −350,618 (−14.9%) | June 30, 2026 |
| 19 | Morgan Stanley - Brokerage Accounts | 1.79% | 1.9M | $72.5M | −297,431 (−13.2%) | June 30, 2026 |
| 20 | State Street Corp | 1.68% | 1.8M | $68.0M | +111,104 (+6.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 16.5M shares and 7 cut 7.6M.
EWTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.68% | 2.9M | $108.2M | −3,906 (−0.1%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.71% | 1.9M | $69.0M | −21,376 (−1.1%) | September 30, 2026 |
| 3 | Strategic Advisers Fidelity US TtlStk | 1.42% | 1.5M | $57.4M | −1.3M (−45.1%) | August 31, 2026 |
| 4 | American Century Small Cap Growth Inv | 0.79% | 856K | $31.8M | — | June 30, 2026 |
| 5 | Victory Pioneer Select Mid Cap Growth A | 0.73% | 794K | $29.5M | +71,215 (+9.8%) | June 30, 2026 |
| 6 | Fidelity Small Cap Index | 0.72% | 782K | $29.1M | +6,562 (+0.8%) | July 31, 2026 |
| 7 | Janus Henderson Global Life Sciences D | 0.70% | 764K | $28.4M | +21,789 (+2.9%) | August 31, 2026 |
| 8 | Janus Henderson Triton D | 0.70% | 760K | $28.3M | +120,162 (+18.8%) | August 31, 2026 |
| 9 | Janus Henderson Hrzn Biotec E2 USD | 0.69% | 749K | $27.9M | — | June 30, 2026 |
| 10 | Janus Henderson Glb Life Scn I2 USD | 0.67% | 732K | $27.2M | +83,761 (+12.9%) | August 31, 2026 |
| 11 | Fidelity Select Biotechnology | 0.64% | 699K | $26.0M | — | August 31, 2026 |
| 12 | iShares Russell 2000 Growth ETF | 0.62% | 669K | $24.9M | −847 (−0.1%) | September 30, 2026 |
| 13 | Janus Global Life Science AUSD | 0.60% | 648K | $24.1M | +47,569 (+7.9%) | June 30, 2026 |
| 14 | Fidelity Small Cap Growth | 0.59% | 643K | $23.9M | — | July 31, 2026 |
| 15 | iShares Biotechnology ETF | 0.59% | 637K | $23.7M | −4,824 (−0.8%) | September 30, 2026 |
| 16 | Driehaus Small Cap Growth Institutional | 0.52% | 560K | $20.8M | +38,284 (+7.3%) | July 31, 2026 |
| 17 | Janus Henderson Venture D | 0.45% | 486K | $18.1M | +68,082 (+16.3%) | August 31, 2026 |
| 18 | Heptagon Driehaus US Sm Cp Eq C USD Acc | 0.43% | 471K | $17.5M | +22,153 (+4.9%) | August 31, 2026 |
| 19 | Heptagon Driehaus US Micro Cap Eq C$ Acc | 0.43% | 467K | $17.4M | — | August 31, 2026 |
| 20 | AB Small Cap Growth A | 0.42% | 458K | $17.0M | −92,244 (−16.8%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
EWTX insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Joanne M Donovan | Sell | $32.31 | 28,662 | $926,069 |
| 2026-01-21 | Badreddin Edris | Sell | $29.44 | 115,471 | $3.4M |
| 2025-11-12 | Alan J Russell | Sell | $21.12 | 100,000 | $2.1M |
| 2025-11-11 | Jonathan C Fox | Buy | $18.64 | 10,700 | $199,448 |
| 2025-08-26 | Alan J Russell | Sell | $14.60 | 100,000 | $1.5M |
| 2025-08-12 | Alan J Russell | Sell | $13.39 | 1,907 | $25,535 |
| 2025-08-12 | Joanne M Donovan | Sell | $13.39 | 2,862 | $38,322 |
| 2025-08-12 | John R Moore | Sell | $13.39 | 2,098 | $28,092 |
| 2025-08-12 | Kevin Koch | Sell | $13.39 | 7,972 | $106,745 |
| 2025-08-12 | R Michael Carruthers | Sell | $13.39 | 1,428 | $19,121 |
| 2025-05-02 | Alan J Russell | Sell | $16.45 | 1,551 | $25,514 |
| 2025-05-02 | Joanne M Donovan | Sell | $16.45 | 5,187 | $85,326 |
| 2025-05-02 | John R Moore | Sell | $16.45 | 1,930 | $31,748 |
| 2025-05-02 | Kevin Koch | Sell | $16.45 | 4,276 | $70,340 |
| 2025-05-02 | R Michael Carruthers | Sell | $16.45 | 1,314 | $21,615 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
EWTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns EWTX
Institutional investors own 112.3% of Edgewise Therapeutics's shares and insiders 0.49%. The largest holder is Orbimed Advisors LLC with 14.29% of the shares (15.5M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 7 reduced their stake in the latest filings. Short interest is 14.56% of the float, or 6.94 days of average trading volume. The share count rose 406.1% since 2020.
Related: EWTX analyst forecast, EWTX key metrics. See the EWTX stock overview for the latest quote and news.
EWTX ownership FAQ
Who owns the most Edgewise Therapeutics stock?
The largest shareholders of Edgewise Therapeutics are Orbimed Advisors LLC (14.29%), Paradigm Biocapital Advisors LP (9.41%), RA Capital Management, LLC (7.73%), BlackRock Inc (6.08%), Jupiter Topco LLC (5.59%).
What percentage of Edgewise Therapeutics is owned by institutions?
Institutions hold 112.3% of Edgewise Therapeutics's shares outstanding; insiders hold 0.49%.
Which funds own Edgewise Therapeutics?
The largest fund holders of Edgewise Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.68%), iShares Russell 2000 ETF (1.71%), Strategic Advisers Fidelity US TtlStk (1.42%), American Century Small Cap Growth Inv (0.79%), Victory Pioneer Select Mid Cap Growth A (0.73%).
What is Edgewise Therapeutics's short interest?
11.2M shares of Edgewise Therapeutics were sold short, 14.56% of the float; at the average daily volume it would take 6.94 days to cover.
Are insiders buying or selling Edgewise Therapeutics?
Of the latest 15 reported insider transactions in Edgewise Therapeutics (since May 2, 2025), 1 were purchases and 14 were sales.
How many shares of Edgewise Therapeutics are outstanding?
Edgewise Therapeutics has 108.6M shares outstanding, of which 74.3M are in the public float.